kamau was founded by Matthew Porteus, Valentin Barsan in 2023.

Who are kamau's investors?

kamau's investors include Khosla Ventures, Modi Ventures, Neva Sgr..

How much funding has kamau raised?

kamau has disclosed $5M raised across 1 round.

Where is kamau headquartered?

kamau is headquartered in Austin, US.

kamau

Austin, US · Founded 2023 · Delaware corporation · 3 known investors

kamautx.com ↗

Kamau Therapeutics develops targeted gene integration therapies to treat serious and life-threatening genetic diseases. The company is a clinical-stage biotech firm focused on next-generation gene correction.

BiotechDeep TechHealthtech

Founders & leadership

kamau was founded in 2023 by Matthew Porteus and Valentin Barsan.

Matthew PorteusCo-founder

Valentin BarsanCo-founder

Board

Raymond KelleherBoard director

Ness BerminghamBoard director

Investors · 3

Khosla VenturesMenlo Park · $5K – $50M

Modi VenturesHouston

Neva Sgr.Turin

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2025

▶$5MraisedJun 2025 · 6 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Raymond KelleherDirector
Matthew PorteusExecutive Officer, Director
Valentin BarsanExecutive Officer, Director
Ness BerminghamDirector

Offering amount: $10M
Amount sold: $5M
First sale: May 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Kenaitx3 shared keywordsKenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease. Its lead program, RNDP-001, is being evaluated in the REPLACE Phase 1b/2a clinical trial for idiopathic Parkinson's disease.

Kano Therapeutics3 shared keywordsKano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.

Companies competing with kamau for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does kamau do?: Kamau Therapeutics develops targeted gene integration therapies to treat serious and life-threatening genetic diseases. The company is a clinical-stage biotech firm focused on next-generation gene correction.
Who founded kamau?: kamau was founded by Matthew Porteus, Valentin Barsan in 2023.
Who are kamau's investors?: kamau's investors include Khosla Ventures, Modi Ventures, Neva Sgr..
How much funding has kamau raised?: kamau has disclosed $5M raised across 1 round.
Where is kamau headquartered?: kamau is headquartered in Austin, US.